Esperion Therapeutics Inc (NAS:ESPR)
$ 2.08 -0.03 (-1.41%) Market Cap: 394.08 Mil Enterprise Value: 445.93 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 54/100

Esperion Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 13, 2021 / 01:30PM GMT
Release Date Price: $26.21 (+0.73%)
Chad Jason Messer
Needham & Company, LLC, Research Division - Senior Analyst

All right. Hello, everybody. Thanks for joining us at the Needham Virtual Health Care Conference. My name is Chad Messer. I'm a senior biotech analyst here at Needham & Company. It is my pleasure to be speaking today with Tim Mayleben, CEO of Esperion, to discuss progress at the company. And I think we're just going to jump right into it.

So good morning, Tim. I really want to start by congratulating Esperion for your execution over the last year. I mean we're in a global pandemic, but you guys launched 2 drugs. You delivered a Japanese deal, debt financing. How have you guys managed so well in this challenging environment?

Timothy M. Mayleben
Esperion Therapeutics, Inc. - President, CEO & Director

Well, Chad, so first off, I just want to thank you for -- well, for you and your colleagues here at Needham for hosting us today. As you highlighted, 2020 was not the year any of us expected it to be. But I think one thing that has driven us for, well, most of the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot